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Summary Four hundred and fifteen males and 367 females who had invasive malignant tumours of the
salivary glands as their first cancer diagnosed in Connecticut between 1935 and 1978 were identified and
followed 2342 and 2868 person-years respectively. Overall a slight excess of second primary cancers (relative
risk 1.35) was observed. Significant excesses were noted for respiratory cancers in males (relative risk 2.8) and
for ovarian cancer (relative risk 5.3) but not breast cancer (relative risk 1.3) in women. Possible reasons for
excesses at these sites are discussed, but it seems most likely they are related to small number variation.
The aetiology of salivary gland malignancy is
generally unknown, although exposure to ionizing
radiation has been identified as a risk factor in
humans (Modan et al., 1974; Hempelmann et al.,
1975; Takeichi et al., 1976; National Academy of
Sciences, 1980). Geographic variation, with a high
risk among Eskimos (Wallace et al., 1963; Lanier et
al., 1976) and residents of Scotland (Lennox et al.,
1978), suggests other as yet unidentified factors.
Experimental studies in mice have demonstrated a
high risk of salivary gland malignancy after
infection with polyoma virus (Gross, 1953). Vitamin
A deficiency has also been suggested to be a
contributing factor from studies on rats (Rowe et
al., 1970).
Berg et al. (1968) first drew attention to an excess
risk of breast cancer in women who had had
previous salivary gland malignancy and suggested
that both cancers might have a common aetiology.
However other studies have not confirmed the 8-
fold excess risk found in the initial report, one
reporting a much lower but still significant excess
(Prior & Waterhouse, 1977), while others reporting
no significant increase (Moertel & Elveback, 1969;
Dunn et al., 1972).
We undertook a review of second primaries
following salivary gland cancer in the hope of
clarifying this issue. For this purpose we used the
Connecticut Tumour Registry. Schoenberg (1977)
has previously summarized the records of this
registry from the period 1935-1964. He found only
19 patients with second primaries following salivary
gland first primary cancer and noted significant
excesses in male breast cancer (1 case found, 0.0
expected) and female bladder cancer (2 cases found,
0.23 expected). Since 1964, new cases have been
added, and the older records have been reviewed
and updated to provide more accurate information.
We note in particular that Schoenberg used in situ
as well as invasive malignancy, whereas this study
is restricted to invasive primary malignancies.
Methods
All residents of Connecticut who had invasive
malignacies of the salivary glands as their first
primary cancer reported to the Connecticut
Tumour Registry from 1935-1978 were eligible for
study. The ICD-0 code system was used for the
classification of all malignancies; tumours of
ectopic salivary gland cells were thus not included,
in accord with this code. Persons who had an
uncertain period of follow-up (6 persons), or who
were diagnosed only by death certificate or autopsy
(37 persons) were excluded.
A second primary cancer was defined as any
invasive malignancy occurring 2 or more months
after the diagnosis of the first primary. The
diagnosis of the pathologist was accepted as
correct, and no attempt was made to verify the
diagnosis. Non-melanoma skin cancers and
carcinoma-in-situ were excluded. Five malignancies
occurring within 2 months of the diagnosis of the
salivary gland primary (lymphoma, colon, prostate,
nervous system and salivary of a different
histology) were considered to be simultaneous
primaries and excluded.
Person-years at risk were calculated from the
date of diagnosis of the primary cancer to either
date of diagnosis of the second primary, date of
death, date lost to follow-up, or December 31,
1978, whichever occurred first. Expected numbers
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of second primary cancers were calculated by
multiplying the age (5y-age groups), sex, calendar-
time and site-specific Connecticut cancer incidence
rates by the appropriate person-years at risk
(Monson, 1974). Relative risks (RR) were
computed using the ratio of observed to expected
(O/E) cases and approximate 95% confidence
intervals (C.I.) for the RR were computed assuming
the observed number of cancers were distributed as
a Poisson variable (Monson, 1974).
Results
Seven hundred and eighty-two patients with
salivary gland primaries were reported between
1935 and 1978. Most were parotoid gland in origin
(74%), and 96.3% were confirmed by histological
examination. A wide variety of cell types were
present, including adenocarcinoma (18%),
mucoepidermoid carcinoma (16%), mixed cell
tumours (15%), squamous cell carcinomas (14%)
and adenocystic carcinomas (11%) as the most
common types. There was no major difference
between the 415 males and the 367 females in mean
age at diagnosis (males 58.3 y; females 55.6y), but
females on the average were observed longer than
males (males 5.6y; females 7.8y). The total follow-
up was 2342 person-years for males and 2868
person-years for females.
Invasive second primaries were reported in 30
males (22.96 expected) and 29 females (20.68
expected). Fifty (85%) of the 59 second primaries
were histologically confirmed. Although neither
male nor female excess was separately statistically
significant, both together constituted a slight but
significant excess over expected (O/E 59/43.64; RR
1.35; 95% C.I. 1.03-1.74). The second primaries
were diagnosed up to 40 years following the initial
primary. In 3 patients there was no information
about the site of the second primary.
The list of second primary diagnoses is provided
in Table 1. Only 2 cancers were diagnosed
significantly more frequently than expected.
Respiratory cancers (primarily cancer of the
bronchus/lung) were diagnosed in 12 males,
whereas 4.29 were expected (RR 2.8; 95% C.I. 1.4-
4.9). However, only 7 cases were histologically
confirmed. The interval between salivary and
respiratory cancer was 3, 13, 18, 23 and 43 mo with
the remaining 8 cases occurring 8-26 y after the
diagnosis of salivary gland malignancy. Ovarian
cancers occurred in 5 women, whereas 0.95 were
expected (RR 5.3; 95% C.I. 1.7-12.3). All ovarian
cancer diagnoses were histologically confirmed.
interval between salivary and ovarian cancer was 4,
15, 34, 106 and 179 mo. All but one first salivary
Table I Second primary malignancies following salivary
gland cancer
Site
Total
Buccal
(Lip-3; tongue-1)
Digestive
Osophagus
Stomach
Large intestines
Rectum
Liver/gall bladder
Pancreas
Other:
Respiratory cancers
Bronchus/lung/trachea
Other:
Bone
Melanoma
Prostate
Bladder
Kidney and other urinary
Brain and other nervous
All lymph/hematopoetic
Hodgkin's disease
Leukaemia
Breast
Female genital
Cervix
Corpus uteri
Ovary
Other female genital
Other or unknown
Male
Obs./Exp.
30/22.96
4/1.28
Female
Obs./Exp.
29/20.68
0/0.35
7/7.55 9/6.45
0/0.52 0/0.13
2/1.52 1/0.88
1/2.66 5/3.01
2/1.56 1/1.21
0/0.37 0/0.45
1/0.77 1/0.64
1/0.15 0/0.13
12/4.29* 2/0.96
10/3.70* 2/0.86
2/0.59 0/0.10
0/0.03 0/0.03
0/0.21 0/0.21
5/4.07
0/1.61 2/0.54
0/0.59 0/0.32
0/0.24 0/0.20
0/1.55 1/1.32
0/0.14 0/0.12
0/0.71 1/0.53
1/0.05 7/5.45
6/3.52
0/0.77
1/1.58
5/0.95*
0/0.22
1/1.49 2/1.33
*Excess significant P<0.05.
gland malignancies were diagnosed in women over
age 70y (55, 71, 73, 74 and 79).
The initial therapy (within the first 4 months of
diagnosis) used to treat the primary salivary gland
malignancy included surgery (65.5%), radiation
plus surgery (17.3%), radiation alone (8.6%), and
other (8.6%). Analysis by type of therapy revealed
that the excesses of respiratory and ovarian cancer
occurred even among those patients treated only by
surgery, although the excess was significant only in
the case of respiratory cancers. The numbers in the
remaining subgroups were too small to show
meaningful differences by type of cancer.SECOND PRIMARIES AFTER SALIVARY GLAND CANCER 385
Table II Risk of breast cancer in women who have had prior salivary gland cancer
Number Patient Expected Observed Relative
of years of breast breast risk
Study patients follow-up cancer cancer (RR)
Berg et al. (1968) 396 1652 0.9 7 7.8*
Moertel & Elveback (1969) 297 3033 4.0 4 1.0
Dunn et al. (1972) 349 2443 4.2 8 1.9
Prior & Waterhouse (1977) 453 2315 2.6 6 2.3*
Present study 367 2868 5.4 7 1.3
*P<0.05.
Breast cancer among females occurred as a
second primary in 7 patients, whereas 5.45 were
expected (RR 1.3; 95% C.I. 0.5-2.7). The ages at
diagnosis of salivary gland cancer in these women
were 38, 41, 49, 65, 66, 67 and 86y. Interestingly,
one male also developed cancer of the breast,
whereas almost no cases (0.05) would be expected.
Four persons had 2 or more invasive separate
primaries following salivary gland cancer. A 40y-
old male had salivary followed by colon and male
genital. A 60y-old female had salivary followed by
colon and then breast. A 73 y-old female had
salivary followed by lung and then melanoma; and
an 89y-old female had salivary followed by ovarian
and then corpus uteri and then bladder.
Discussion
The large number of person-years of follow-up and
the careful calculation of age- and sex-specific
expected incidence cases (adjusted for calendar-time
of diagnosis) from the same population as the cases
make this study especially useful. Despite this, we
were unable to confirm a significant increase in risk
of breast cancer, as has been reported by Berg et al.
(1968) and by Prior & Waterhouse (1977), but not
found by Moertel & Elveback (1969) or Dunn et al.
(1972). (Table II) The small excess we observed
was not statistically significant, but the relative risk
of 1.3 fell within the confidence intervals of all
earlier studies except that by Berg et al. (1968).
Comparisons between studies are difficult,
particularly with regard to computing the expected
number of breast cancer cases. The most important
variable affecting breast cancer incidence is the age
of the cohort under follow-up, since breast cancer
incidence increases with age. This in turn is a
function of both age at entry into the study and
duration of follow-up. We presume that the higher
number of expected breast cancers calculated for
the women in this study is related to the higher
average age at entry into our study and the longer
follow-up, but the data given in earlier reports are
inadequate to document this precisely. Patients
diagnosed as having their first salivary gland cancer
at <60y of age had no excess of breast cancer
(O/E 3/3.25; RR 0.9). Thus there was no higher
risk in women with a younger age at diagnosis of
salivary gland cancer, as suggested by Prior &
Waterhouse (1977). Among women first diagnosed
>60y, the relative risk was 1.8 (O/E 4/2.25).
The excess of respiratory malignancies among
males and ovarian cancer among females were
significant. Bronchial cancer excesses were also
observed in the study by Prior & Waterhouse
(1977). They raise the possibility that the excesses
might be due to an underestimate of the expected
number of bronchial cancers, since the rates of lung
cancer changed dramatically over the period of
their study but were averaged to provide an
expected number. In our study the expected number
was adjusted by the calendar-year the subject
entered the study. No excess of ovarian cancer has
been previously reported.
There are many reasons, in addition to chance,
why excesses might occur. The aetiology of the
tumours may share common environmental and/or
genetic risk factors, as yet unknown. Smoking, for
example, is a known risk factor in lung cancer, but
it is apparently unrelated to the aetiology of a
salivary gland cancer (Keller, 1969). It is also
possible that late, unrecorded therapy with other
agents might have increased the risk of malignancy
at other sites, as therapy was recorded only if it
occurred within 4 mo of the diagnosis of the first
primary malignancy.
Non-aetiologically related factors, such as mis-
diagnoses of metastatic disease and more complete
tumour detection in patients being followed for a
previous cancer, may also influence the excess risks
observed in the follow-up group. As 4 respiratory
and 2 ovarian second primary cancers occurred386 R.J. BIGGAR et al.
within 2y of the original salivary gland cancer, we
suggest that these may be examples of non-
aetiologically related tumours. If so, it is likely that
there is no significant excess of second tumours
following salivary gland primary cancer, at least
that can be detected in a study of this size.
References
BERG, J.W., HUTTER, R.V.P. & FOOTE, F.W. Jr. (1968). The
unique association between salivary gland cancer and
breast cancer. J. Am. Med. Assoc., 204, 771.
DUNN, J.E. Jr., BRAGG, K.U., SAUTTER, C. & GORDIPEE,
C. (1972). Breast cancer risk following a major salivary
gland carcinoma. Cancer, 29, 1343.
GROSS, L. (1953). A filterable agent, recovered from Ak
leukaemic extracts, causing salivary gland carcinomas
in C3H mice. Proc. Soc. Exp. Biol. Med., 83, 414.
HEMPELMANN, L.H., HALL, W.J., PHILLIPS, M., COOPER,
R.A. & AMES, W.R. (1975). Neoplasms in persons
treated with X-rays in infancy: Fourth survey in 20
years. J. Natl Cancer Inst., 55, 519.
KELLER, A.Z. (1969). Residence, age, race, and related
factors in the survival and associations with salivary
gland tumours. Am. J. Epidemiol., 90, 269.
LANIER, A.P., BENDER, T.R., BLOT, W.J., FRAUMENI, J.F.
Jr. & HURLBURT, W.B. (1976). Cancer incidence in
Alaskan natives. Int. J. Cancer, 18, 409.
LENNOX, B., CLARKE, J.A., DRAKE, F. & EWEN, S.W.B.
(1978). Incidence of salivary gland tumours in
Scotland: accuracy of national records. Br. Med. J., i,
687.
MODAN, B., BAIDATZ, D., MART, H., STEINITZ, R. &
LEVIN, S.G. (1974). Radiation-induced head and neck
tumors. Lancet, i, 277.
MOERTEL, C.G. & ELVEBACK, L.R. (1969). The
association between salivary gland cancer and breast
cancer. J. Am. Med. Assoc., 210, 306.
MONSON, R.R. (1974). Analysis of relative survival and
proportional mortality. Comp. Biomed. Res., 7, 325.
NATIONAL ACADEMY OF SCIENCES, NATIONAL
RESEARCH COUNCIL (1980). The Effects on
Populations and Exposure to Low Levels of Ionizing
Radiation. Washington, D.C.
PRIOR, P. & WATERHOUSE, J.A.H. (1977). Second primary
cancers in patients with tumours of the salivary
glands. Br. J. Cancer, 36, 362.
ROWE, N.H., GRAMMER, F.C., WATSON, F.R. &
NICKERSON, N.H. (1970). An environmental influence
upon salivary gland neoplasia in rats. Cancer, 26, 436.
SCHOENBERG, B.S. (1977). Multiple primary malignant
neoplasms. The Connecticut experience, 1935-1964.
Recent Results Cancer Res., 58,
TAKEICHI, N., HIROSE, F. & YAMAMOTO H. (1976).
Salivary gland tumours in atomic bomb survivors,
Hiroshima, Japan. I. Epidemiological observations.
Cancer, 38, 2462.
WALLACE, A.C., MACDOUGALL, J.T. & HILDES, J.A.
(1963). Salivary gland tumors in Canadian Eskimos.
Cancer, 16, 1338.